

Xiaohua Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3482818/publications.pdf>

Version: 2024-02-01

93
papers

2,361
citations

236925

25
h-index

254184

43
g-index

94
all docs

94
docs citations

94
times ranked

3399
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in diagnosis and treatment of metastatic cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e43.	2.2	338
2	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	1.6	183
3	Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β 4/SNAI1/SIRT3 signaling pathway. <i>Oncogene</i> , 2018, 37, 4164-4180.	5.9	91
4	circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 718-730.	5.1	91
5	Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis. <i>International Journal of Oncology</i> , 2019, 54, 1719-1733.	3.3	78
6	FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. <i>Molecular Cancer</i> , 2021, 20, 45.	19.2	69
7	The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1650-1657.	2.5	60
8	Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. <i>Nature Communications</i> , 2014, 5, 4682.	12.8	59
9	Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: A systematic review. <i>European Journal of Cancer</i> , 2015, 51, 1751-1759.	2.8	56
10	The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 883.	2.6	52
11	A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. <i>Scientific Reports</i> , 2016, 6, 25408.	3.3	47
12	Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e77.	2.2	46
13	Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. <i>Oncotarget</i> , 2015, 6, 4968-4975.	1.8	44
14	Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. <i>Cancer Treatment Reviews</i> , 2022, 106, 102385.	7.7	44
15	Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer. <i>PLoS ONE</i> , 2016, 11, e0156101.	2.5	39
16	Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. <i>BMC Cancer</i> , 2016, 16, 43.	2.6	37
17	Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5025-5036.	3.6	37
18	BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. <i>Oncogene</i> , 2021, 40, 2711-2724.	5.9	36

#	ARTICLE	IF	CITATIONS
19	PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. <i>Scientific Reports</i> , 2015, 5, 14035.	3.3	35
20	Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e500.	4.0	34
21	Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 466-470.	1.4	31
22	Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. <i>Oncotarget</i> , 2017, 8, 51840-51847.	1.8	30
23	Clinical Significance of Programmed Death Ligand-1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. <i>PLoS ONE</i> , 2017, 12, e0170879.	2.5	29
24	Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery. <i>Current Treatment Options in Oncology</i> , 2016, 17, 44.	3.0	28
25	Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6647-6656.	2.0	28
26	ERBB2 mutation: A promising target in non-squamous cervical cancer. <i>Gynecologic Oncology</i> , 2018, 148, 311-316.	1.4	27
27	A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e65.	2.2	27
28	An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2452-2458.	7.0	27
29	Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2017, 147, 589-596.	1.4	25
30	Mutational analysis of <i>KRAS</i> and its clinical implications in cervical cancer patients. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e4.	2.2	25
31	Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e18.	2.2	24
32	The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2953-2958.	1.5	24
33	miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 562-568.	1.8	24
34	Conization Using an Electrosurgical Knife for Cervical Intraepithelial Neoplasia and Microinvasive Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131790.	2.5	21
35	The effect of visceral obesity on clinicopathological features in patients with endometrial cancer: a retrospective analysis of 200 Chinese patients. <i>BMC Cancer</i> , 2016, 16, 209.	2.6	20
36	Circ0004390 promotes cell proliferation through sponging miR-198 in ovarian cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 14-20.	2.1	20

#	ARTICLE	IF	CITATIONS
37	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 97.e1-97.e16.	1.3	20
38	Appendiceal mucinous neoplasm mimics ovarian tumors: Challenges for preoperative and intraoperative diagnosis and clinical implication. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2120-2125.	1.0	19
39	Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1244-1251.	2.5	19
40	Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 550.	2.6	19
41	Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 131-138.	1.0	18
42	Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. , 2022, 10, e003831.		18
43	Ovarian cancer circulating extracellular vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis. <i>BMC Cancer</i> , 2019, 19, 1095.	2.6	17
44	Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. <i>Journal of Ovarian Research</i> , 2020, 13, 89.	3.0	16
45	Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). <i>Journal of Ovarian Research</i> , 2017, 10, 7.	3.0	15
46	Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e62.	2.2	14
47	CASP7 variants modify susceptibility to cervical cancer in Chinese women. <i>Scientific Reports</i> , 2015, 5, 9225.	3.3	13
48	Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma. <i>BMC Cancer</i> , 2017, 17, 317.	2.6	13
49	Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2021, 14, 12.	3.0	13
50	<p>Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5213-5223.	1.9	12
51	Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. <i>Aging</i> , 2020, 12, 11398-11415.	3.1	12
52	A risk model of gene signatures for predicting platinum response and survival in ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 39.	3.0	12
53	Menstrual pattern after abdominal radical trachelectomy. <i>Oncotarget</i> , 2017, 8, 53146-53153.	1.8	11
54	Validation of the new FIGO staging system (2009) for vulvar cancer in the Chinese population. <i>Gynecologic Oncology</i> , 2015, 137, 274-279.	1.4	10

#	ARTICLE	IF	CITATIONS
55	A novel highly sensitive and specific flow cytometry system for cervical cancer screening. <i>Gynecologic Oncology</i> , 2015, 139, 52-58.	1.4	10
56	Adjuvant concurrent chemoradiation followed by chemotherapy for high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 58-63.	1.4	10
57	HNRNP1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway. <i>Oncogene</i> , 2021, 40, 4770-4782.	5.9	10
58	Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers. <i>Oncotarget</i> , 2017, 8, 32848-32855.	1.8	10
59	Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 653-661.	7.0	10
60	Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. <i>Cancer Medicine</i> , 2020, 9, 5899-5907.	2.8	9
61	18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications. <i>BMC Cancer</i> , 2019, 19, 226.	2.6	8
62	Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer. <i>Thrombosis Research</i> , 2020, 190, 129-134.	1.7	8
63	Diagnostic accuracy of 18F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3392-3398.	2.0	8
64	A new method of surgical margin assuring for abdominal radical trachelectomy in frozen section. <i>European Journal of Cancer</i> , 2015, 51, 734-741.	2.8	7
65	Abdominal scar characteristics as a predictor of cervical stenosis after abdominal radical trachelectomy. <i>Oncotarget</i> , 2016, 7, 37755-37761.	1.8	7
66	RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells. <i>Cancer Cell International</i> , 2015, 15, 41.	4.1	6
67	Downregulation of eukaryotic initiation factor 4A1 improves radiosensitivity by delaying DNA double strand break repair in cervical cancer. <i>Oncology Letters</i> , 2017, 14, 6976-6982.	1.8	6
68	Telomere length in cervical exfoliated cells, interaction with HPV genotype, and cervical cancer occurrence among high-risk HPV-positive women. <i>Cancer Medicine</i> , 2019, 8, 4845-4851.	2.8	6
69	<p>Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 913-919.	1.9	6
70	ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6106-TPS6106.	1.6	6
71	Extraperitoneal laparoscopy for para-aortic lymphadenectomy in endometrial carcinoma staging: an approach with higher efficiency. <i>World Journal of Surgical Oncology</i> , 2021, 19, 323.	1.9	6
72	Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis. <i>Gynecologic Oncology</i> , 2020, 156, 357-362.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia. <i>Frontiers in Oncology</i> , 2021, 11, 643986.	2.8	5
74	Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 687899.	2.8	5
75	The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma. <i>Cancer Biomarkers</i> , 2020, 27, 189-194.	1.7	4
76	Clinicopathologic and survival analysis of patients with adenoid cystic carcinoma of vulva: single-institution experience. <i>International Journal of Clinical Oncology</i> , 2020, 25, 2144-2150.	2.2	4
77	Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 538-546.	1.7	4
78	Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 364-364.	1.7	4
79	Extracellular vesicle-derived miR-320a targets ZC3H12B to inhibit tumorigenesis, invasion, and angiogenesis in ovarian cancer. <i>Discover Oncology</i> , 2021, 12, 51.	2.1	4
80	Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	4
81	Niraparib treatment for patients with <i>BRCA</i> -mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536.	2.4	4
82	A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 571671.	2.8	3
83	Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 632195.	2.8	3
84	The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients. <i>BMC Surgery</i> , 2022, 22, 81.	1.3	3
85	Retrotransposons: Jump to Cancer?. <i>Trends in Cancer</i> , 2021, 7, 577-579.	7.4	2
86	Clinicopathologic characteristics and survival analysis in stage IVB cervical cancer with hematogenous metastasis. <i>Translational Cancer Research</i> , 2019, 8, 1217-1223.	1.0	2
87	Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 315-319.	1.7	1
88	Abstract 2044: Genomic scar score: a robust model to predict recombination repair deficient based on genomic instability. , 2021, , .		1
89	The development of a homologous recombination deficiency (HRD) score to identify HR-deficient tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18085-e18085.	1.6	1
90	Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6034-6034.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Reoperation with Total Hysterectomy after Incomplete Surgery Is Helpful in Patients with Incidentally Diagnosed Uterine Leiomyosarcoma. Gynecologic and Obstetric Investigation, 2021, 86, 408-414.	1.6	0
92	GIs-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.. Journal of Clinical Oncology, 2020, 38, 6032-6032.	1.6	0
93	Mutational analysis of <i>KRAS</i> and its clinical implications in cervical cancer patients. Journal of Gynecologic Oncology, 0, 29, .	2.2	0